{"id":"W2495512985","doi":"10.1200/jco.2016.34.4_suppl.192","title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Interim analysis; Hazard ratio; Hepatocellular carcinoma; Internal medicine; Randomized controlled trial; Phases of clinical research; Oncology; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002559894,0.0003086816,0.00466496,0.0002290632,0.00003631702,0.00000378003,0.000242083,0.0003319862,0.000339951],"category_scores_gemma":[0.001233639,0.0001670228,0.0005433256,0.0002658807,0.0004667476,0.0001739093,0.00006183826,0.000710975,0.00001022101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005258239,"about_ca_system_score_gemma":0.001657796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009508069,"about_ca_topic_score_gemma":0.0001792074,"domain_scores_codex":[0.9937958,0.001150656,0.003680906,0.0003722423,0.0005839784,0.0004164377],"domain_scores_gemma":[0.991432,0.004204026,0.002936865,0.0003096778,0.0006884864,0.0004290154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7563238,0.02494332,0.1840549,0.00002337773,0.001064379,0.0009913186,0.0003750847,0.00001237128,0.0004211707,0.00001316639,0.0003548265,0.0314223],"study_design_scores_gemma":[0.8415822,0.1112942,0.04257767,0.0001376714,0.001622684,0.00001522955,0.0002023138,0.00006609243,0.000379252,0.00003259125,0.001931632,0.0001584772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936976,0.000519942,0.00007149702,0.001442846,0.00180783,0.002025251,0.000009314782,0.00001037816,0.0004152935],"genre_scores_gemma":[0.9980434,0.000438167,0.0004370046,0.000274501,0.0004362306,0.00004862151,0.000005420154,0.00003178578,0.000284911],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1414773,"threshold_uncertainty_score":0.6810991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09144095418322526,"score_gpt":0.4539521059192045,"score_spread":0.3625111517359793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}